New dissolving pill aims to protect kidneys in liver transplant patients
NCT ID NCT07267208
First seen Dec 08, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This study looks at whether switching to a new, easy-to-take dissolving form of the hepatitis B drug entecavir is safe and helps protect kidney function in adults who have had a liver transplant. About 82 stable patients who have been on standard entecavir for at least a year will take the new tablet for 48 weeks. The main goal is to see if their kidney function (measured by eGFR) improves or stays stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.